Company intelligence / Profile preview

Medyria

Winterthur, Zurich/ZH, Switzerlandmedyria.com ↗

Ownership: Private
Development stage: Other

Overview

Medyria has developed a proprietary blood flow velocity sensing technology, initially offered as an OEM sensor component. Its flagship product, the PyCath microcatheter, enables simultaneous pressure and direct blood flow velocity measurements during catheter-based cardiovascular procedures. This allows comprehensive physiological assessment of both obstructive and microvascular coronary disease. The company has completed preclinical development of PyCath and launched a pilot clinical trial ("KENOBI Trial") in March 2025 to evaluate safety and efficacy for integrated coronary assessment—an important step toward regulatory approval.

Therapeutic areas: Cardiovascular
Modalities: DeviceSensorMicrocatheter device
Industry: Surgical Medical Devices

Partnerships

Collaboration with Clinical Accelerator on KENOBI Trial

Beyond the preview

Go deeper on Medyria.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Medyria.

Explore the full profile